Microbix biosystems announces the addition of a biotechnology executive Patrick Walsh to its board of directors
Microbix Biosystems has appointed Patrick Walsh to its board of directors with immediate effect today.
Walsh is a well-respected healthcare industry CEO who brings extensive experience in leading companies in successful development, product launch and commercialisation efforts in numerous product categories.
Mr Walsh is currently CEO and a member of the board of directors of Atairgin Technologies, a privately held company with a platform technology utilising bio-active lipids in certain diagnostic and therapeutic applications.
He is a past president, chief operating officer, and board member of Gensia Sicor Pharmaceuticals.
Prior to Gensia Sicor, he spent ten years at Fujisawa Pharmaceutical in executive management roles and has also served as an industry consultant to the global pharmaceutical industry.
"Microbix has developed unique and valuable product opportunities.
I am pleased to join the Microbix board and look forward to working with Bill and his team!" he stated.
"Pat's knowledge of the global market, including his past experience in commercialising unique biotherapeutics, promises to serve Microbix very well at this time in our development," said William Gastle, Microbix's president and CEO.
"We welcome his advice as we advance our lead target, the drug urokinase, successfully to the US market."
